- Browse/Search the Program
Search
Browse By Time
Browse By Person
Browse By Division
Browse By Session or Event Type
- Information Menu
Search Tips
How to Build a Personal Program
- Navigation and Settings Menu
Personal Schedule
Change Preferences / Time Zone
The Prevalence and Policy Consequences of Support for Regulating Off-Label Semaglutide Prescriptions
Thu, April 4, 4:45 to 6:15pm CDT (4:45 to 6:15pm CDT), TBABrief Overview
We examine the prevalence of support for off-label semaglutide prescribing (e.g., Ozempic) as a weight management drug, and experimentally investigate how safety and supply shortage considerations influence regulatory attitudes.